candesartan has been researched along with Metabolic Syndrome in 17 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the relationship between plasma plasminogen activator inhibitor-1 (PAI-1) and angiotensin II (Ang II) changes during treatment with imidapril and candesartan in hypertensive patients with metabolic syndrome." | 9.15 | Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome. ( Derosa, G; Fogari, R; Lazzari, P; Maffioli, P; Mugellini, A; Zoppi, A, 2011) |
| "We compared the effects of telmisartan with those of candesartan, on insulin sensitivity, the serum levels of various adipocytokines and oxidative stress." | 9.14 | Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients. ( Awata, T; Ikebukuro, K; Inukai, K; Ito, D; Katayama, S; Kurihara, S; Ono, H; Sumita, T; Watanabe, M, 2010) |
| "SHR/NDmcr-cp (SHRcp), a rat model of human metabolic syndrome, were divided into four groups, and were administered (i) vehicle, (ii) candesartan (an ARB) 0." | 7.78 | Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Koibuchi, N; Nakamura, T; Ogawa, H; Sueta, D; Toyama, K; Yamamoto, E; Yasuda, O, 2012) |
| "The aim of the study was to elucidate normalizing effect of candesartan on disturbed thrombocytic hemostasis in patients with arterial hypertension and metabolic syndrome." | 7.77 | [Dynamics of primary hemostasis activity in patients with arterial hypertension and metabolic syndrome treated with candesartan]. ( Medvedev, IN; Simonenko, VB; Tolmachev, VV, 2011) |
| " This study was designed to examine the effect of an ARB candesartan on subclinical atherosclerosis assessed by cardio-ankle vascular index (CAVI) in comparison with calcium channel blockers (CCBs) alone in hypertensive patients with metabolic syndrome (MetS)." | 7.76 | Blood pressure-independent effect of candesartan on cardio-ankle vascular index in hypertensive patients with metabolic syndrome. ( Bokuda, K; Ichihara, A; Itoh, H; Kinouchi, K; Mito, A; Sakoda, M, 2010) |
| "The present study by using the telemedicine system clearly demonstrated that telmisartan has a strong effect on reducing morning home BP, and a good effect on lipid metabolism in patients with metabolic syndrome." | 5.19 | Effectiveness of using long-acting angiotensin II type 1 receptor blocker in Japanese obese patients with metabolic syndrome on morning hypertension monitoring by using telemedicine system (FUJIYAMA study). ( Kinoshita, S; Nakamoto, H; Nishida, E; Ryuzaki, M; Sone, M, 2014) |
| "To evaluate the relationship between plasma plasminogen activator inhibitor-1 (PAI-1) and angiotensin II (Ang II) changes during treatment with imidapril and candesartan in hypertensive patients with metabolic syndrome." | 5.15 | Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome. ( Derosa, G; Fogari, R; Lazzari, P; Maffioli, P; Mugellini, A; Zoppi, A, 2011) |
| "We compared the effects of telmisartan with those of candesartan, on insulin sensitivity, the serum levels of various adipocytokines and oxidative stress." | 5.14 | Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients. ( Awata, T; Ikebukuro, K; Inukai, K; Ito, D; Katayama, S; Kurihara, S; Ono, H; Sumita, T; Watanabe, M, 2010) |
| "The authors assessed the effect of an angiotensin receptor blocker (candesartan)-based regimen on electrocardiographic left ventricular hypertrophy (ECG-LVH) in 276 patients with hypertension, including 141 with the metabolic syndrome (MS)." | 5.13 | Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with the metabolic syndrome: data from the SARA Study. ( Barrios, S; Barrios, V; Calderón, A; Echarri, R; Escobar, C; Fernandez, R; Ferrer, E; Navarro-Cid, J, 2008) |
| "SHR/NDmcr-cp (SHRcp), a rat model of human metabolic syndrome, were divided into four groups, and were administered (i) vehicle, (ii) candesartan (an ARB) 0." | 3.78 | Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Koibuchi, N; Nakamura, T; Ogawa, H; Sueta, D; Toyama, K; Yamamoto, E; Yasuda, O, 2012) |
| "The aim of the study was to elucidate normalizing effect of candesartan on disturbed thrombocytic hemostasis in patients with arterial hypertension and metabolic syndrome." | 3.77 | [Dynamics of primary hemostasis activity in patients with arterial hypertension and metabolic syndrome treated with candesartan]. ( Medvedev, IN; Simonenko, VB; Tolmachev, VV, 2011) |
| " This study was designed to examine the effect of an ARB candesartan on subclinical atherosclerosis assessed by cardio-ankle vascular index (CAVI) in comparison with calcium channel blockers (CCBs) alone in hypertensive patients with metabolic syndrome (MetS)." | 3.76 | Blood pressure-independent effect of candesartan on cardio-ankle vascular index in hypertensive patients with metabolic syndrome. ( Bokuda, K; Ichihara, A; Itoh, H; Kinouchi, K; Mito, A; Sakoda, M, 2010) |
| "The expressions of angiotensinogen, angiotensin converting enzyme, angiotensin II receptor type 1 in mesenteric adipose tissue were significantly increased in rats with metabolic syndrome compared with those in rats on normal diet (P <0." | 3.73 | [Renin-angiotensin system in mesenteric adipose tissues in rats with metabolic syndrome]. ( Cao, TB; Li, ZB; Liu, DY; Ma, LQ; Wang, LJ; Zhang, LL; Zhang, YP; Zhu, ZM, 2006) |
| "The metabolic syndrome is a risk factor for the development of chronic kidney disease." | 1.35 | Pioglitazone enhances the antihypertensive and renoprotective effects of candesartan in Zucker obese rats fed a high-protein diet. ( Haruna, Y; Kashihara, N; Kobayashi, S; Komai, N; Namikoshi, T; Sasaki, T; Satoh, M; Tomita, N, 2008) |
| "Hypoxia caused by sleep apnea might be associated with an increased risk of cardiovascular events in subjects with metabolic syndrome." | 1.33 | Angiotensin-II receptor blocker exerts cardioprotection in diabetic rats exposed to hypoxia. ( Furuya, E; Hayashi, T; Inamoto, S; Kitaura, Y; Matsumura, Y; Mori, T; Nakano, D; Okuda, N; Sakai, A; Sohmiya, K; Tazawa, N; Yamashita, C, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 10 (58.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kinoshita, S | 1 |
| Ryuzaki, M | 1 |
| Sone, M | 1 |
| Nishida, E | 1 |
| Nakamoto, H | 1 |
| Namikoshi, T | 1 |
| Tomita, N | 1 |
| Satoh, M | 1 |
| Haruna, Y | 1 |
| Kobayashi, S | 1 |
| Komai, N | 1 |
| Sasaki, T | 1 |
| Kashihara, N | 1 |
| Georgescu, EF | 1 |
| Hu, J | 1 |
| Tiwari, S | 2 |
| Riazi, S | 1 |
| Hu, X | 1 |
| Wang, X | 1 |
| Ecelbarger, CM | 2 |
| Yamauchi, T | 1 |
| Kadowaki, T | 1 |
| Tian, F | 1 |
| Luo, R | 1 |
| Zhao, Z | 1 |
| Wu, Y | 1 |
| Ban, Dj | 1 |
| Rash, A | 1 |
| Sinha, RK | 1 |
| Bokuda, K | 1 |
| Ichihara, A | 1 |
| Sakoda, M | 1 |
| Mito, A | 1 |
| Kinouchi, K | 1 |
| Itoh, H | 1 |
| Watanabe, M | 1 |
| Inukai, K | 1 |
| Sumita, T | 1 |
| Ikebukuro, K | 1 |
| Ito, D | 1 |
| Kurihara, S | 1 |
| Ono, H | 1 |
| Awata, T | 1 |
| Katayama, S | 1 |
| Jadhav, R | 1 |
| Dodd, T | 1 |
| Smith, E | 1 |
| Bailey, E | 1 |
| Delucia, AL | 1 |
| Russell, JC | 1 |
| Madison, R | 1 |
| Potter, B | 1 |
| Walsh, K | 1 |
| Jo, H | 1 |
| Rocic, P | 1 |
| Fogari, R | 1 |
| Zoppi, A | 1 |
| Mugellini, A | 1 |
| Maffioli, P | 1 |
| Lazzari, P | 1 |
| Derosa, G | 1 |
| Simonenko, VB | 1 |
| Medvedev, IN | 1 |
| Tolmachev, VV | 1 |
| Sueta, D | 1 |
| Nakamura, T | 1 |
| Dong, YF | 1 |
| Kataoka, K | 1 |
| Koibuchi, N | 1 |
| Yamamoto, E | 1 |
| Toyama, K | 1 |
| Yasuda, O | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Kishi, T | 1 |
| Hirooka, Y | 1 |
| Konno, S | 1 |
| Sunagawa, K | 1 |
| Inamoto, S | 1 |
| Hayashi, T | 1 |
| Tazawa, N | 1 |
| Mori, T | 1 |
| Yamashita, C | 1 |
| Nakano, D | 1 |
| Matsumura, Y | 1 |
| Okuda, N | 1 |
| Sohmiya, K | 1 |
| Sakai, A | 1 |
| Furuya, E | 1 |
| Kitaura, Y | 1 |
| Ma, LQ | 1 |
| Zhang, LL | 1 |
| Zhang, YP | 1 |
| Wang, LJ | 1 |
| Li, ZB | 1 |
| Cao, TB | 1 |
| Liu, DY | 1 |
| Zhu, ZM | 1 |
| Escobar, C | 1 |
| Barrios, V | 1 |
| Calderón, A | 1 |
| Barrios, S | 1 |
| Echarri, R | 1 |
| Navarro-Cid, J | 1 |
| Ferrer, E | 1 |
| Fernandez, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Nighttime Losartan on Prognosis of Nocturnal Hypertension Patients Undergoing Continous Ambulatory Peritoneal Dialysis[NCT03692013] | Phase 4 | 68 participants (Anticipated) | Interventional | 2018-12-01 | Not yet recruiting | ||
| Effect of Nighttime Valsartan on Prognosis of Nocturnal Hypertension Patients Undergoing Maintenance Hemodialysis[NCT03594825] | Phase 4 | 68 participants (Anticipated) | Interventional | 2018-11-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for candesartan and Metabolic Syndrome
| Article | Year |
|---|---|
Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Fat | 2008 |
[Anti-metabolic syndrome effects of candesartan].
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; D | 2009 |
5 trials available for candesartan and Metabolic Syndrome
| Article | Year |
|---|---|
Effectiveness of using long-acting angiotensin II type 1 receptor blocker in Japanese obese patients with metabolic syndrome on morning hypertension monitoring by using telemedicine system (FUJIYAMA study).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asian People; Benzimidazoles | 2014 |
Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients.
Topics: Adiponectin; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2010 |
Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome.
Topics: Adolescent; Adult; Aged; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conver | 2011 |
Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Arteries; Benzimidazoles; Benzoates; Biphenyl Compounds; Bl | 2012 |
Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Arteries; Benzimidazoles; Benzoates; Biphenyl Compounds; Bl | 2012 |
Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Arteries; Benzimidazoles; Benzoates; Biphenyl Compounds; Bl | 2012 |
Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Arteries; Benzimidazoles; Benzoates; Biphenyl Compounds; Bl | 2012 |
Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with the metabolic syndrome: data from the SARA Study.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Blood Pre | 2008 |
10 other studies available for candesartan and Metabolic Syndrome
| Article | Year |
|---|---|
Pioglitazone enhances the antihypertensive and renoprotective effects of candesartan in Zucker obese rats fed a high-protein diet.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Dietary Protei | 2008 |
Regulation of angiotensin II type I receptor (AT1R) protein levels in the obese Zucker rat kidney and urine.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biomarker | 2009 |
Blockade of the RAS increases plasma adiponectin in subjects with metabolic syndrome and enhances differentiation and adiponectin expression of human preadipocytes.
Topics: Adipocytes; Adiponectin; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzy | 2010 |
The effect of chronic candesartan therapy on the metabolic profile and renal tissue cytokine levels in the obese Zucker rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Cytokines; Die | 2010 |
Blood pressure-independent effect of candesartan on cardio-ankle vascular index in hypertensive patients with metabolic syndrome.
Topics: Ankle; Antihypertensive Agents; Arteries; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Caroti | 2010 |
Angiotensin type I receptor blockade in conjunction with enhanced Akt activation restores coronary collateral growth in the metabolic syndrome.
Topics: Adenoviridae; Angiotensin II Type 2 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; | 2011 |
[Dynamics of primary hemostasis activity in patients with arterial hypertension and metabolic syndrome treated with candesartan].
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Female; | 2011 |
Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Bl | 2012 |
Angiotensin-II receptor blocker exerts cardioprotection in diabetic rats exposed to hypoxia.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2006 |
[Renin-angiotensin system in mesenteric adipose tissues in rats with metabolic syndrome].
Topics: Adipocytes; Adipose Tissue; Angiotensin II; Angiotensinogen; Animals; Benzimidazoles; Biphenyl Compo | 2006 |